Ya-chen Zhang1, Rui-ming Chen, Bao-jing Lu, Ye-zhi Rong. 1. Department of Internal Cardiology, Xinhua Hospital affiliated to Shanghai Jiaotong Medical University School of Medicine, Shanghai, China. zhangyachen65@yahoo.com.cn
Abstract
OBJECTIVE: To confirm the effect of Shengmai Injection (, SMI) in improving cardiac function in patients with acute coronary syndrome (ACS) and to explore its influence on inflammatory reaction in patients. METHODS:Ninety ACS patients were randomized into two groups, the control group treated with conventional therapy and the SMI group treated with SMI. The patients' cardiac function was noted and the content of high sensitive C-reactive protein (hs-CRP) in venous blood was measured before treatment and 1 week and 3 weeks after treatment, so as to observe and compare their changes between the two groups. RESULTS: The cardiac output, stroke volume and ejection fraction in the SMI group after 3 weeks of treatment were all higher than those in the control group (P<0.05). The serum content of hs-CRP was reduced in both groups (P<0.05), but the reduction in the SMI group was more significant than that in the control group (P<0.05). CONCLUSION: SMI could improve the cardiac function and further inhibit the inflammatory reaction in patients with ACS.
RCT Entities:
OBJECTIVE: To confirm the effect of Shengmai Injection (, SMI) in improving cardiac function in patients with acute coronary syndrome (ACS) and to explore its influence on inflammatory reaction in patients. METHODS: Ninety ACS patients were randomized into two groups, the control group treated with conventional therapy and the SMI group treated with SMI. The patients' cardiac function was noted and the content of high sensitive C-reactive protein (hs-CRP) in venous blood was measured before treatment and 1 week and 3 weeks after treatment, so as to observe and compare their changes between the two groups. RESULTS: The cardiac output, stroke volume and ejection fraction in the SMI group after 3 weeks of treatment were all higher than those in the control group (P<0.05). The serum content of hs-CRP was reduced in both groups (P<0.05), but the reduction in the SMI group was more significant than that in the control group (P<0.05). CONCLUSION:SMI could improve the cardiac function and further inhibit the inflammatory reaction in patients with ACS.
Authors: L M Biasucci; G Liuzzo; R L Grillo; G Caligiuri; A G Rebuzzi; A Buffon; F Summaria; F Ginnetti; G Fadda; A Maseri Journal: Circulation Date: 1999-02-23 Impact factor: 29.690
Authors: L M Biasucci; G D'Onofrio; G Liuzzo; G Zini; C Monaco; G Caligiuri; M Tommasi; A G Rebuzzi; A Maseri Journal: J Am Coll Cardiol Date: 1996-03-01 Impact factor: 24.094
Authors: G Liuzzo; L M Biasucci; J R Gallimore; R L Grillo; A G Rebuzzi; M B Pepys; A Maseri Journal: N Engl J Med Date: 1994-08-18 Impact factor: 91.245